HNN3.0

Miltenyi Biotec

Company (Industry)

www.miltenyibiotec.com/de-en/Bergisch Gladbach, Germany
1 profile visit

About

Miltenyi is one of Europe’s largest biomedical companies providing integrated solutions—from cell isolation and analysis to clinical‑scale manufacturing—that support the entire translational workflow.

The company seeks to empower researchers and clinicians by providing comprehensive platforms—spanning sample preparation, cell separation, flow cytometry, and GMP‑grade cell processing—that facilitate the translation of discoveries into therapies.

Miltenyi prioritizes technological innovation, investing in next‑generation tools that enable deep phenotypic, molecular, and functional insights into complex biological systems.

Its technology development is rooted in precision engineering and evidence‑driven practices, ensuring reliability, reproducibility, and compliance with stringent international standards.

Ultimately, the company’s overarching goal is to advance scientific progress and improve patient outcomes by driving technological leadership across biomedical research and cellular therapy.

Representatives

Scientific Director - Grants and Collaborations @ R&D Department

Miltenyi Biotec

Marketplace (2)

  • Project cooperation

    Immunoadsorption (IA) for management of post-infection long-term conditions

    Immunoadsorption is investigated as a promising approach to treat post-infection long-term conditions like Post Covid ME/CFS.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    Author

    Scientific Director - Grants and Collaborations @ R&D Department at Miltenyi Biotec

    Bergisch Gladbach, Germany

  • Project cooperation

    Contributing manufacturing technologies and clinical trial experience to a European network of Centres of Excellence for ATMPs

    Miltenyi serves the full ATMP value chain, from enabling technologies and GMP manufacturing platforms to real world clinical deployment.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    Author

    Scientific Director - Grants and Collaborations @ R&D Department at Miltenyi Biotec

    Bergisch Gladbach, Germany